You are here

  • Home
  • Archive
  • Volume 69, Issue 11
  • Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan

Article Text

Article menu
Download PDFPDF
Letter
Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan
  1. Caleb Zelenietz,
  2. Janet Pope
  1. University of Western Ontario, Schulich School of Medicine and Dentistry, St Joseph's Health Care, London, Ontario, Canada
  1. Correspondence to Dr Janet Pope, University of Western Ontario, Schulich School of Medicine and Dentistry, St Joseph's Health Care, 268 Grosvenor Street, London, Ontario, N6A 4V2, Canada; janet.pope{at}sjhc.london.on.ca

https://doi.org/10.1136/ard.2009.122960

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Digital ulcers (DUs) cause significant morbidity in systemic sclerosis (SSc), occurring in 50% of patients with the disease.1 Patients report the impact of Raynaud's phenomenon and DU as worse than lung and gastrointestinal problems associated with SSc.2 The Health Assessment Questionnaire (HAQ)3 score is higher in patients with SSc with DU than in those without DU.4 A subset of the Health Assessment Questionnaire Disability Index (HAQ-DI) has been used for determining hand function,5 which is associated with work disability in patients with SSc.6 The purpose of this study was to determine if the HAQ score improved when a DU healed and if it worsened when a DU occurred.

    Data were obtained from Actelion Pharmaceuticals Ltd for this post hoc analysis. All patients participating in the RAndomised Placebo-controlled Investigation of Digital ulcers …

    View Full Text

    Footnotes

    • Funding Data for this study were from the RAPIDS-1 and RAPIDS-2 trials funded by Actelion Pharmaceuticals Ltd.

    • Competing interests JP has received payment from Actelion Pharmaceuticals Ltd for consultancy.

    • Provenance and peer review Not commissioned; externally peer reviewed.